50% Off! Beat the market in 2025 with InvestingProCLAIM SALE

Biden removes sanctions from Chinese institute in push for fentanyl help

Published 11/16/2023, 09:25 AM
Updated 11/16/2023, 01:56 PM
© Reuters. The Department of Commerce building is seen in Washington, U.S., January 26, 2022.      REUTERS/Joshua Roberts

By Alexandra Alper and Michael Martina

WASHINGTON (Reuters) -The Biden administration on Thursday removed the Chinese Ministry of Public Security's Institute of Forensic Science from a trade sanction list, part of a bid to convince Beijing to do more to halt the flow of the synthetic opioid fentanyl into the United States.

Washington put the institute on the list in 2020 over alleged abuses against Uyghurs and other minority groups, effectively barring it from receiving most goods from U.S. suppliers.

Former Chinese ambassador to the U.S. Qin Gang last year described it as "shocking" that the U.S., which had expressed frustration over Beijing's lack of cooperation on fentanyl, would sanction an institute he described as essential to controlling the drug.

The Chinese embassy in Washington did not immediately respond to a request for comment.

Reuters had previously reported the institute would be removed as Biden sought more cooperation from Beijing on fentanyl in a meeting with China's President Xi Jinping on Wednesday in San Francisco at the Asia-Pacific Economic Cooperation (APEC) forum.

As part of the meeting, the men agreed to create a working group on counter-narcotics cooperation. The White House's National Security Council did not respond to a request for comment on what, beyond creating the working group, China pledged to do to stem shipments of the deadly narcotic.

The move was criticized by human rights activists and Republicans, who accused the Biden administration of going soft on Beijing over its treatment of Uyghurs.

Rayhan Asat, a human rights lawyer of Uyghur heritage, said she recognized the pressing issue posed by fentanyl, but that the U.S. decision raised questions about U.S. commitment to addressing China's rights abuses.

"The United States has a legal obligation, under federal law, to address atrocity crimes once they have been determined as such. The question then arises: should addressing one issue take precedence over addressing the genocide? Can't we address both?" she said.

© Reuters. FILE PHOTO: U.S. President Joe Biden gives thumbs-up as he walks with Chinese President Xi Jinping at Filoli estate on the sidelines of the Asia-Pacific Economic Cooperation (APEC) summit, in Woodside, California, U.S., November 15, 2023. REUTERS/Kevin Lamarque

Blocking fentanyl "precursor" chemicals has been a priority for Washington as the rate of overdose deaths involving the drug more than tripled from 2016 through 2021, according to the U.S. Centers for Disease Control and Prevention (CDC).

The removal, according to a notice posted in the Federal Register, came after a "removal proposal" was received and reviewed, the department said in the posting, by a committee composed of representatives of the departments of Commerce, State, Defense, Energy, and sometimes, the Treasury.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.